6Haring HU & Mehnert H. Pathogenesis of type 2(non - insulin -dependent)diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle. Diabetologia 1993 ;36:176 - 182.
7Bergstrom RW, Newell - Morris LL, Leonetti DL, et al. Association of elevated fasting C - peptide level and increased intra adbomihal fat distributin with development of NIDDM in Japanese - American men. Diabetes 1990; 39:104 - 111.
8Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectvely in muscle causes insulin resistance and glucose intolerance. Nature Medicine 2000;6:924-928.
9Edelman SV. Type Ⅱ diabetes mellitus. Advances in internal medicine 1998;43:449-500.
10Kobayashi M. Effects of current therapeutic interventions on insulin resistance. Diabetes, Obesity & Metabolism 1999; 1: S32 -S40.
7Subhashini Yaturu,Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men[J].Diabet Care,2007,30(6):1574-1576.
8Andrew B,Grey MD.Skeletal Toxicity of Thiazolidinediones[J].Annal Interl Med,2008,48 (7):563.
9Lipsembe LI,GomesT,Levesque LE,et al.Thiazolibdinediones and cardiovascular outeomes in older patients with diabetes[J].J AMA,2007,298(22):2634-2643.
10FDA news FDA add boxed warning for heart-rehted risk to antrdinbetes drug A vandial[EB/OL].2007-11-14.http//www.fdagov/bbs/topies/NEWS/2007/NEW0173 himl.
